Identification of a dual inhibitor of SRPK1 and CK2 that attenuates pathological angiogenesis of macular degeneration in mice

Molecular Pharmacology

Volumn 88, Issue 2, 2015, Pages 316-325

  Morooka, Satoshi ^a   Hoshina, Mitsuteru ^b   Kii, Isao ^a   Okabe, Takayoshi ^c   Kojima, Hirotatsu ^c   Inoue, Naoko ^d   Okuno, Yukiko ^a   Denawa, Masatsugu ^a   Yoshida, Suguru ^b   Fukuhara, Junichi ^e   Ninomiya, Kensuke ^a   Ikura, Teikichi ^b   Furuya, Toshio ^d   Nagano, Tetsuo ^c   Noda, Kousuke ^e   Ishida, Susumu ^e   Hosoya, Takamitsu ^b   Ito, Nobutoshi ^b   Yoshimura, Nagahisa ^a   Hagiwara, Masatoshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Laboratory of Structural Biology Medical Research Institute Tokyo Medical and Dental University ^*  (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; ENZYME INHIBITOR; MOLECULAR LIBRARY; NICOTINAMIDE; PIPERIDINE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PYRIMIDINONE DERIVATIVE; SRPIN340; SRPIN803; SRPK1 PROTEIN, HUMAN; THIADIAZOLE DERIVATIVE;

ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CHOROIDAL NEOVASCULARIZATION; DISEASE MODEL; HUMAN; MACULAR DEGENERATION; METABOLISM; MOLECULAR DOCKING; MOLECULAR LIBRARY; MOUSE; PATHOLOGY; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; TOPICAL DRUG ADMINISTRATION; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, TOPICAL; ANIMALS; CASEIN KINASE II; CELL LINE; CHOROIDAL NEOVASCULARIZATION; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; MACULAR DEGENERATION; MICE; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; NIACINAMIDE; PIPERIDINES; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINONES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZOLES;

EID: 84939795708     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.097345     Document Type: Article

References (64)

1. Aguilar E, Dorrell MI, Friedlander D, Jacobson RA, Johnson A, Marchetti V, Moreno SK, Ritter MR, and Friedlander M (2008) Chapter 6. Ocular models of angiogenesis. Methods Enzymol 444:115-158.
2. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, and Rennel ES et al. (2011) WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20:768-780.
3. Baell JB and Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719-2740.
4. Daub H, Blencke S, Habenberger P, Kurtenbach A, Dennenmoser J, Wissing J, Ullrich A, and Cotten M (2002) Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. J Virol 76:8124-8137.
5. De Moliner E, Moro S, Sarno S, Zagotto G, Zanotti G, Pinna LA, and Battistutta R (2003) Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J Biol Chem 278:1831-1836.
6. Dong Z, Noda K, Kanda A, Fukuhara J, Ando R, Murata M, Saito W, Hagiwara M, and Ishida S (2013) Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization. Mol Vis 19:536-543.
7. Dulak J, Deshane J, Jozkowicz A, and Agarwal A (2008) Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 117:231-241.
8. Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
9. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, and Cousins SW (2003) Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3586-3592.
10. Feng D, Welker S, Körbel C, Rudzitis-Auth J, Menger MD, Montenarh M, and Laschke MW (2012) Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions. Angiogenesis 15:243-252.
11. Ferrara N, Gerber HP, and LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676.
12. Ferris FL, 3rd, Fine SL, and Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102:1640-1642.
13. Fitzgerald CE, Patel SB, Becker JW, Cameron PM, Zaller D, Pikounis VB, O'Keefe SJ, and Scapin G (2003) Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat Struct Biol 10:764-769.
14. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, and Semenza GL (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205-38211.
15. Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, Suzuki M, Yamamoto N, Herzenberg LA, and Herzenberg LA et al. (2006) Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci USA 103:11329-11333.
16. Gammons MV, Dick AD, Harper SJ, and Bates DO (2013) SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 54:5797-5806.
17. Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, and Bates DO (2014) Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer 111:477-485.
18. Gragoudas ES, Adamis AP, Cunningham ET, Jr, Feinsod M, and Guyer DR VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816.
19. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, Elner VM, Elner SG, and Sternberg P, Jr (2002) Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8:119-126.
20. Hathaway GM and Traugh JA (1982) Casein kinases - multipotential protein kinases. Curr Top Cell Regul 21:101-127.
21. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, and Yancopoulos GD et al.; VIEW 1 and VIEW 2 Study Groups (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537-2548.
22. Hu SI, Katz M, Chin S, Qi X, Cruz J, Ibebunjo C, Zhao S, Chen A, and Glass DJ (2012) MNK2 inhibits eIF4G activation through a pathway involving serine-arginine-rich protein kinase in skeletal muscle. Sci Signal 5:ra14.
23. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, and Holmgren E et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342.
24. Klein R, Wang Q, Klein BE, Moss SE, and Meuer SM (1995) The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 36:182-191.
25. Kramerov AA, Saghizadeh M, Caballero S, Shaw LC, Li Calzi S, Bretner M, Montenarh M, Pinna LA, Grant MB, and Ljubimov AV (2008) Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites. Mol Cell Biochem 316:177-186.
26. Lin J, Handschin C, and Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361-370.
27. Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369:1-15.
28. Ljubimov AV, Caballero S, Aoki AM, Pinna LA, Grant MB, and Castellon R (2004) Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci 45:4583-4591.
29. Maharaj AS and D'Amore PA (2007) Roles for VEGF in the adult. Microvasc Res 74:100-113.
30. Martin D, Galisteo R, and Gutkind JS (2009) CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284:6038-6042.
31. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, and Ferris FL, 3rd Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388-1398.
32. Meggio F and Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349-368.
33. Meisner H, Heller-Harrison R, Buxton J, and Czech MP (1989) Molecular cloning of the human casein kinase II alpha subunit. Biochemistry 28:4072-4076.
34. Mottet D, Ruys SP, Demazy C, Raes M, and Michiels C (2005) Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer 117:764-774.
35. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, and Vagin AA (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67:355-367.
36. Mylonis I and Giannakouros T (2003) Protein kinase CK2 phosphorylates and activates the SR protein-specific kinase 1. Biochem Biophys Res Commun 301:650-656.
37. Ngo JC, Chakrabarti S, Ding JH, Velazquez-Dones A, Nolen B, Aubol BE, Adams JA, Fu XD, and Ghosh G (2005) Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol Cell 20:77-89.
38. Ngo JC, Gullingsrud J, Giang K, Yeh MJ, Fu XD, Adams JA, McCammon JA, and Ghosh G (2007) SR protein kinase 1 is resilient to inactivation. Structure 15:123-133.
39. Nikolakaki E, Drosou V, Sanidas I, Peidis P, Papamarcaki T, Iakoucheva LM, and Giannakouros T (2008) RNA association or phosphorylation of the RS domain prevents aggregation of RS domain-containing proteins. Biochim Biophys Acta 1780:214-225.
40. Nishida A, Kataoka N, Takeshima Y, Yagi M, Awano H, Ota M, Itoh K, Hagiwara M, and Matsuo M (2011) Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun 2:308.
41. Nolen B, Ngo J, Chakrabarti S, Vu D, Adams JA, and Ghosh G (2003) Nucleotide-induced conformational changes in the Saccharomyces cerevisiae SR protein kinase, Sky1p, revealed by X-ray crystallography. Biochemistry 42:9575-9585.
42. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, and Ladomery MR et al. (2010) Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to antiangiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 285:5532-5540.
43. Noy P, Gaston K, and Jayaraman PS (2012a) Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes. Leuk Res 36:1434-1437.
44. Noy P, Sawasdichai A, Jayaraman PS, and Gaston K (2012b) Protein kinase CK2 inactivates PRH/Hhex using multiple mechanisms to de-repress VEGF-signalling genes and promote cell survival. Nucleic Acids Res 40:9008-9020.
45. Ogawa Y and Hagiwara M (2012) Challenges to congenital genetic disorders with "RNA-targeting" chemical compounds. Pharmacol Ther 134:298-305.
46. Okabe K, Kobayashi S, Yamada T, Kurihara T, Tai-Nagara I, Miyamoto T, Mukouyama YS, Sato TN, Suda T, and Ema M et al. (2014) Neurons limit angiogenesis by titrating VEGF in retina. Cell 159:584-596.
47. Olsten ME and Litchfield DW (2004) Order or chaos? An evaluation of the regulation of protein kinase CK2. Biochem Cell Biol 82:681-693.
48. Pinna LA (1990) Casein kinase 2: an 'eminence grise' in cellular regulation? Biochim Biophys Acta 1054:267-284.
49. Pollreisz A, Afonyushkin T, Oskolkova OV, Gruber F, Bochkov VN, and Schmidt-Erfurth U (2013) Retinal pigment epithelium cells produce VEGF in response to oxidized phospholipids through mechanisms involving ATF4 and protein kinase CK2. Exp Eye Res 116:177-184.
50. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, and Kim RY; MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431.
51. Sakurai E, Anand A, Ambati BK, van Rooijen N, and Ambati J (2003) Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3578-3585.
52. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, and Murphy WJ (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34-40.
53. Schaal S, Kaplan HJ, and Tezel TH (2008) Is there tachyphylaxis to intravitreal antivascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199-2205.
54. Seddon JM and Chen CA (2004) The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 44:17-39.
55. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, and Tano Y (2008) Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol (Copenh) 86:372-376.
56. Tatar O, Yoeruek E, Szurman P, Bartz-Schmidt KU, Adam A, Shinoda K, Eckardt C, Boeyden V, Claes C, and Pertile G et al.; Tübingen Bevacizumab Study Group (2008) Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 126:782-790.
57. Trott O and Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455-461.
58. Unger GM, Davis AT, Slaton JW, and Ahmed K (2004) Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets 4:77-84.
59. Ventrice P, Leporini C, Aloe JF, Greco E, Leuzzi G, Marrazzo G, Scorcia GB, Bruzzichesi D, Nicola V, and Scorcia V (2013) Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother 4:S38-42.
60. Wang P, Zhou Z, Hu A, Ponte de Albuquerque C, Zhou Y, Hong L, Sierecki E, Ajiro M, Kruhlak M, and Harris C et al. (2014) Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell 54:378-391.
61. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, and McCoy A et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67:235-242.
62. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, and Guha A (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208:313-326.
63. Xu J, Liu X, Jiang Y, Chu L, Hao H, Liua Z, Verfaillie C, Zweier J, Gupta K, and Liu Z (2008) MAPK/ERK signalling mediates VEGF-induced bone marrow stem cell differentiation into endothelial cell. J Cell Mol Med 12 (6A):2395-2406.
64. Xue Y, Wan PT, Hillertz P, Schweikart F, Zhao Y, Wissler L, and Dekker N (2013) X-ray structural analysis of tau-tubulin kinase -1 and its interactions with small molecular inhibitors. ChemMedChem 8:1846-1854.